Jovana Nikolic, MD

All articles by Jovana Nikolic, MD

• Researchers develop PBC prognostic model via machine learning

  A randomized survival forest model in machine learning was used to construct a prognostic model for cirrhosis in primary biliary cholangitis (PBC).

• Case report shows possible link between genetic defect and PBC

  A study showed a rare case of primary biliary cholangitis (PBC) with features of autoimmune hepatitis in an adolescent with a genetic defect.

• Autotaxin could serve as noninvasive PBC biomarker, study shows

  Autotaxin may be an effective noninvasive biomarker for the diagnosis and prognosis of primary biliary cholangitis (PBC), researchers stated.

• Case report: PSC complicated by dangerous liver abscess

  The formation of liver abscess caused by Klebsiella pneumoniae can be life-threatening in patients with primary sclerosing cholangitis (PSC).

• Ultrasound may successfully identify PBC disease stage

  Ultrasound imaging may be a valuable tool to assess and predict the progression of primary biliary cholangitis (PBC), according to a study.

• CymaBay’s PBC therapy shows promising results in phase 3

  The latest findings from a post-hoc analysis of the phase 3 ENHANCE study were published in the journal Hepatology,

• Study: Intense itching significantly lowers quality of life in PBC

  A recent study shows intense itching, also known as pruritus, significantly reduces the life quality of patients with primary biliary cholangitis (PBC).

• Study finds potential link between PBC and osteoporosis

  Patients with PBC may suffer a greater risk of developing osteoporosis, but researchers have not yet identified a definitive relationship between the two.

• High neutrophil-to-lymphocyte ratio may predict poor outcomes in PBC treatment

  A recent study shows a high neutrophil-to-lymphocyte ratio may predict poor response to ursodeoxycholic acid in primary biliary cholangitis (PBC).

• Ipsen, Genfit score FDA priority review for investigational PBC therapy

  The FDA has accepted a New Drug Application (NDA) for elafibranor, an investigational therapeutic for the treatment of primary biliary cholangitis (PBC).